BridgeMD
Tests treatment safety and results for Endometriosis
Official title A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
ClinicalTrials.gov ID: NCT07260669
What this study is testing
What is Vipoglanstat?
Vipoglanstat is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for endometriosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 44, women only
You may be able to join if
- Premenopausal females 18 to \< 45 years of age at the time of Visit 1.
- Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:
- Surgical (via direct visualization or biopsy verified) or
- Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging [MRI].
- History of NMPP significantly affecting daily life confirmed at Visit 1.
You likely can't join if
- Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve...
- Has had more than 2 surgical procedures for endometriosis.
See the full eligibility criteria
- Premenopausal females 18 to \< 45 years of age at the time of Visit 1.
- Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:
- Surgical (via direct visualization or biopsy verified) or
- Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging [MRI].
- History of NMPP significantly affecting daily life confirmed at Visit 1.
- The participant reports moderate, severe, or very severe pain during non-menstrual days in the month prior to Visit 2, based on patient global assessment NMPP.
- Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve entrapments or neuropathies, non-endometriosis-related pelvic adhesive disease...
- Has had more than 2 surgical procedures for endometriosis.
The study team makes the final eligibility decision.
Where it's taking place
- Blagoevgrad, Bulgaria
- Sofia, Bulgaria
- Brno, Czechia
- Olomouc, Czechia
- Pilsen, Czechia
- Vodňany, Czechia
- Budapest, Hungary
- Debrecen, Hungary
- Kaposvár, Hungary
- Genova, Italy
- Bialystok, Poland
- Bydgoszcz, Poland
- Katowice, Poland
- Krakow, Poland
- Lublin, Poland
- Siedlce, Poland
- Skorzewo, Poland
- Szczecin, Poland
- Warsaw, Poland
- Bucharest, Romania
+ 12 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 44 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Blagoevgrad, Bulgaria; Sofia, Bulgaria; Brno, Czechia; Olomouc, Czechia; Pilsen, Czechia; Vodňany, Czechia and 26 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.